Watchdog Nominee Eric Ueland's Health Industry Ties
The nominee to run the Government Accountability Office has consulted and lobbied for the health insurance and pharmaceutical industries — which receive significant revenue from federal programs that routinely come under the office’s oversight.
(Photo by Finn Gomez/Getty Images)
Eric Ueland, the nominee to run Congress’s watchdog agency for the next 15 years, was a former consultant for Humana, a major health insurance company that offers Medicare Advantage plans, according to his financial disclosure.
Federal healthcare programs, including Medicare Advantage, are a routine and major target of audits and reviews by the Government Accountability Office (GAO) — the very agency President Donald Trump nominated Ueland to run.
Get the latest
Weekly newsletter and occasional updates
Last year, in its list of “high-risk” federal programs, GAO wrote that the government “needs to improve the timeliness of Medicare Advantage plan audits to recover significant improper payments.” In its webpage on federal health care spending, GAO states that “federal spending on major health care programs — as a share of GDP — is projected to increase 47% over the next two decades, continuing to contribute to the unsustainable long-term fiscal future of the nation.”
More than a decade ago, Ueland lobbied for the health insurance industry and pharmaceutical companies, which have made hundreds of billions of dollars from growing healthcare spending by the federal government. His lobbying included work on “Medicare Advantage rates” on behalf of America’s Health Insurance Plans, a trade association of health insurance companies now known by its acronym, AHIP. A 2022 New York Times review of Medicare Advantage found that “dozens of fraud lawsuits, inspector general audits and investigations by watchdogs shows how major health insurers exploited the program to inflate their profits by billions of dollars.”
A government watchdog recently found that Humana overcharged the Medicare Advantage program by more than $130 million. There’s no evidence Ueland was involved in the alleged overcharging by Humana, which disputed the findings of the report, and it’s unknown if Ueland worked as a consultant for the insurance giant at the time of the claimed overcharges.
Ueland’s nomination has proven controversial in part due to his current role at OMB. His boss, Russell Vought, has said the GAO “shouldn’t exist.”
Recent polling shows widespread concerns about affordability and the influence of health insurance companies on government policy.
The White House’s Office of Management and Budget (OMB), where Ueland is currently deputy director for management, had no immediate comment in response to a query from POGO Investigates, the news reporting division of the Project On Government Oversight (POGO).
Ueland’s nomination has proven controversial in part due to his current role at OMB. His boss, Russell Vought, has said the GAO “shouldn’t exist.” POGO published a letter from 21 former inspectors general criticizing Ueland’s nomination, and the organization has criticized the rush to confirm Ueland.
“Even widespread recusals could not cure a conflict that reaches the core of GAO’s docket, nor could they restore public and congressional trust that GAO’s legal and audit findings are free from executive-branch influence,” the former inspectors general said of Ueland, citing their concern about whether he would have enough independence from the White House.
Ueland said in a Senate hearing today that, if confirmed as comptroller general, he would “fully discharge those responsibilities.”
“I’m not here as a plant, a stooge, a lackey for anybody,” Ueland said.